Autoantibody signatures in prostate cancer
Autoantibody signatures in prostate cancer
复制标题
DOI：
10.1056/nejmoa051931
复制
发表时间：
2005-09-22
影响因子：
158.5
通讯作者：
Chinnaiyan, AM
中科院分区：
文献类型：
--
作者：
Wang, XJ;Yu, JJ;Chinnaiyan, AM
背景：新的生物标志物，如自身抗体的签名，可能会提高前列腺癌的早期检测。方法：与来自前列腺癌组织的噬菌体展示库，我们开发和使用噬菌体蛋白微阵列分析血清样本从119例前列腺癌患者和138名对照组，样本平均分为训练集和验证集。一个噬菌体肽检测器，从训练集构建了一个独立的验证集的128个血清样本（60例前列腺癌患者和68名对照组）进行了评估。结果：一个22噬菌体肽检测器有88.2%的特异性（95%的置信区间，0.78至0.95）和81.6%的灵敏度（95%的置信区间，0.70至0.90）在区分组与前列腺癌和对照组。在区分前列腺癌组和对照组方面，这组肽的表现优于前列腺特异性抗原（PSA）（自身抗体特征的曲线下面积为0.93; 95%置信区间为0.88至0.97; PSA曲线下面积为0.80; 95%置信区间为0.71至0.88）。Logistic回归分析显示，噬菌体肽组比PSA提供了额外的鉴别力（P
BACKGROUND:New biomarkers, such as autoantibody signatures, may improve the early detection of prostate cancer.METHODS:With a phage-display library derived from prostate-cancer tissue, we developed and used phage protein microarrays to analyze serum samples from 119 patients with prostate cancer and 138 controls, with the samples equally divided into training and validation sets. A phage-peptide detector that was constructed from the training set was evaluated on an independent validation set of 128 serum samples (60 from patients with prostate cancer and 68 from controls).RESULTS:A 22-phage-peptide detector had 88.2 percent specificity (95 percent confidence interval, 0.78 to 0.95) and 81.6 percent sensitivity (95 percent confidence interval, 0.70 to 0.90) in discriminating between the group with prostate cancer and the control group. This panel of peptides performed better than did prostate-specific antigen (PSA) in distinguishing between the group with prostate cancer and the control group (area under the curve for the autoantibody signature, 0.93; 95 percent confidence interval, 0.88 to 0.97; area under the curve for PSA, 0.80; 95 percent confidence interval, 0.71 to 0.88). Logistic-regression analysis revealed that the phage-peptide panel provided additional discriminative power over PSA (P